The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 randomized, double-blind, placebo-controlled study to evaluate LY3537021 for the treatment of chemotherapy-induced nausea and vomiting in patients with malignant disease.
 
Matthew Hayes
Research Funding - Boehringer Ingelheim; Gila Therapeutics; Novo Nordisk; Pfizer
 
Takako Nakajima
Honoraria - Bristol-Myers Squibb Japan; Celltrion Healthcare Japan K.K.; Chugai Pharma; Daiichi Sankyo/UCB Japan; IQVIA SolutionsJapan K.K.; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - FIMECS, Inc.; Shinobi Therapeutics; Thyas Co. Ltd (Inst)
Research Funding - Abbvie (Inst); BTB Therapeutics; Chugai Pharma (Inst); Immunohelix; IQVIA Solutions Japan K.K.; KBBM (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical; Otsuka (Inst); Parexel international inc; Taiho Pharmaceutical (Inst); Taisho Pharmaceutical Holdings (Inst); Takeda (Inst); Thermo Fisher Scientific; Toregem BioPharma Co., Ltd. (Inst); Zymeworks (Inst)
 
Olivia Seecof
No Relationships to Disclose
 
Margarita Majem
Consulting or Advisory Role - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb; Helsinn Therapeutics; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); BMS (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Pfizer; Roche
 
Suresh Chenji
Employment - Eli Lilli and Company
Stock and Other Ownership Interests - Eli Lilli and Company
 
Negin Ashki
Employment - Eli Lilli and Company
Stock and Other Ownership Interests - Eli Lilli and Company
 
Matteo Ceccarelli
Employment - Ei Lilly and Company
Stock and Other Ownership Interests - Ei Lilly and Company
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; Agenus; ALX Oncology; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bexon Clinical Consulting; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Daiichi Sankyo; Debiopharm Group; Eisai; ElmediX; Fosum; Galapagos NV; GlaxoSmithKline; Ipsen; ITeos Therapeutics; Lilly; Merck KGaA; Merck Sharp & Dohme; Microbial Machines; Mirati Therapeutics; Nordic Group; Novartis; Novocure; Pfizer; Pierre Fabre; Sanofi; Seagen; SERVIER; Simcere; Taiho Pharmaceutical; Takeda; Trishula Therapeutics